Compare Aurora Cannabis Inc (ACB) vs Lemonade Inc (LMND) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

Lemonade (LMND) trades at $77.59, up 8.49% in the last session, showing strong momentum with a bullish technical outlook. The stock has consistently beaten earnings expectations in recent quarters, with revenue growth accelerating from $257M in 2022 to $738M in 2025. However, the company remains unprofitable with a -16.44% net income margin, though losses are narrowing. Recent expansion into new states and reinsurance program improvements provide positive catalysts.

While LMND shows promising growth and technical strength, the stock trades above the $71.75 analyst consensus target. The path to profitability remains the key challenge, with negative cash flow from operations and high valuation multiples creating risk. Investors face a trade-off between strong revenue growth and persistent losses in a competitive insurance market.